Favorable mPFS demonstrated in Phase 1/1b as a monotherapy in RSK2-high metastatic breast cancer patients. SAN DIEGO and VANCOUVER, British Columbia, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Phoenix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results